Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Reymann

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Fundamental & Clinical Pharmacology|April 2, 1998
Experimental and clinical methods in the development of anti-Alzheimer drugsH Allain, D Bentué-Ferrer, O Zekri, et al.
Dementia and Geriatric Cognitive Disorders|September 23, 1997
Effect of normal aging and of Alzheimer's disease on, episodic memoryS Le Moal, J M Reymann, V Thomas, et al.
Clinical Neuropharmacology|February 1, 1988
Lack of pharmacokinetic influence on levodopa by bromocriptineD Bentué-Ferrer, H Allain, J M Reymann, et al.
Toxicological European Research. Recherche Europeenne En Toxicologie|July 1, 1979
[Influence of a tributyltin oxide oily aerosol on the exploratory behaviour toward the mouse (author's transl)]R Truhaut, J P Anger, J M Reymann, et al.
Experimental Aging Research|January 1, 1985
Effect of triethyltin chloride on the central aminergic neurotransmitters and their metabolites: relationship with pathophysiology of agingD Bentue-Ferrer, J M Reymann, J Van den Driessche, et al.
Brain Research|December 24, 1997
Lisuride prevents learning and memory impairment and attenuates the increase in extracellular dopamine induced by transient global cerebral ischemia in ratsM A Caldwell, J M Reymann, H Allain, et al.
La Nouvelle Presse Medicale|June 28, 1980
[Does bromocriptine act through the autonomic nervous system?]H Allain, D Bentue-Ferrer, D Pape, et al.
Neuropsychobiology|January 1, 1996
The dopamine agonists lisuride and piribedil protect against behavioural and histological changes following 4-vessel occlusion in the ratM A Caldwell, J M Reymann, D Bentue-Ferrer, et al.
Revue Neurologique|January 17, 2003
[Mild Cognitive Impairment: potential therapeutics]H Allain, D Bentue-Ferrer, S Belliard, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 18, 2005
Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patientsP Gallien, J-M Reymann, G Amarenco, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Fundamental & Clinical Pharmacology|April 2, 1998
Experimental and clinical methods in the development of anti-Alzheimer drugsH Allain, D Bentué-Ferrer, O Zekri, et al.
Dementia and Geriatric Cognitive Disorders|September 23, 1997
Effect of normal aging and of Alzheimer's disease on, episodic memoryS Le Moal, J M Reymann, V Thomas, et al.
Clinical Neuropharmacology|February 1, 1988
Lack of pharmacokinetic influence on levodopa by bromocriptineD Bentué-Ferrer, H Allain, J M Reymann, et al.
Toxicological European Research. Recherche Europeenne En Toxicologie|July 1, 1979
[Influence of a tributyltin oxide oily aerosol on the exploratory behaviour toward the mouse (author's transl)]R Truhaut, J P Anger, J M Reymann, et al.
Experimental Aging Research|January 1, 1985
Effect of triethyltin chloride on the central aminergic neurotransmitters and their metabolites: relationship with pathophysiology of agingD Bentue-Ferrer, J M Reymann, J Van den Driessche, et al.
Brain Research|December 24, 1997
Lisuride prevents learning and memory impairment and attenuates the increase in extracellular dopamine induced by transient global cerebral ischemia in ratsM A Caldwell, J M Reymann, H Allain, et al.
La Nouvelle Presse Medicale|June 28, 1980
[Does bromocriptine act through the autonomic nervous system?]H Allain, D Bentue-Ferrer, D Pape, et al.
Neuropsychobiology|January 1, 1996
The dopamine agonists lisuride and piribedil protect against behavioural and histological changes following 4-vessel occlusion in the ratM A Caldwell, J M Reymann, D Bentue-Ferrer, et al.
Revue Neurologique|January 17, 2003
[Mild Cognitive Impairment: potential therapeutics]H Allain, D Bentue-Ferrer, S Belliard, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 18, 2005
Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patientsP Gallien, J-M Reymann, G Amarenco, et al.
Pageof 6